A cost-effectiveness analysis of consolidation...

Annals of Oncology 2020 / 1

A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland

Panje, C.M., Lupatsch, J.E., Barbier, M., Pardo, E., Lorez, M., Dedes, K.J., Aebersold, D.M., Plasswilm, L., Gautschi, O., Schwenkglenks, M.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.01.007
Date:
January, 2020
File:
PDF, 844 KB
2020
Conversion to is in progress
Conversion to is failed